-
Company Profile
![]()
Sosei Group Corp – Company Profile
Sosei Group Corp (Sosei) is a biopharmaceutical company that develops and commercializes drugs. Its medical products include Ultibro, Seebri, Enerzair, Breezhaler, and Oravi. The company's in-house pipeline programs include H4 antagonist, EP4 antagonist, SARS-CoV-2 MPro, GPR52 agonist and PAR2 mAb. Sosei partnered pipeline program comprises Adenosine A2a antagonist, GLP-1 agonist, CCR6 antagonist, MC4 antagonist, CGRP antagonist, GPR35 agonist, CXCR4 mAb, PAR2 Peptide, targeted GPCR degradation, AI-augmented drug discovery, Ion Channels, mGlu5 NAM and OX2 agonists. It develops medicines in the...
Add to Basket -
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – HTL-0039732 in Head And Neck Cancer Squamous Cell Carcinoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. HTL-0039732 in Head And Neck Cancer Squamous Cell Carcinoma Drug Details: HTL-0039732 is under development...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – HTL-0039732 in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. HTL-0039732 in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Drug Details: HTL-0039732 is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – HTL-0039732 in Gastroesophageal (GE) Junction Carcinomas
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. HTL-0039732 in Gastroesophageal (GE) Junction Carcinomas Drug Details: HTL-0039732 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – HTL-0048149 in Schizophrenia
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. HTL-0048149 in Schizophrenia Drug Details: HTL-0048149 is under development for the treatment of positive symptoms,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – HTL-0039732 in Lung Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. HTL-0039732 in Lung Cancer Drug Details: HTL-0039732 is under development for the treatment of microsatellite...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – HTL-0039732 in Colorectal Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. HTL-0039732 in Colorectal Cancer Drug Details: HTL-0039732 is under development for the treatment of microsatellite...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – HTL-0039732 in Cervical Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. HTL-0039732 in Cervical Cancer Drug Details: HTL-0039732 is under development for the treatment of microsatellite...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – HTL-0039732 in Pancreatic Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. HTL-0039732 in Pancreatic Cancer Drug Details: HTL-0039732 is under development for the treatment of microsatellite...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – HTL-0039732 in Bladder Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. HTL-0039732 in Bladder Cancer Drug Details: HTL-0039732 is under development for the treatment of microsatellite...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – HTL-0039732 in Pheochromocytoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. HTL-0039732 in Pheochromocytoma Drug Details: HTL-0039732 is under development for the treatment of microsatellite stable3...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – HTL-0039732 in Sarcomas
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. HTL-0039732 in Sarcomas Drug Details: HTL-0039732 is under development for the treatment of microsatellite stable3...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – HTL-0039732 in Kidney Cancer (Renal Cell Cancer)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. HTL-0039732 in Kidney Cancer (Renal Cell Cancer) Drug Details: HTL-0039732 is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – HTL-0039732 in Malignant Mesothelioma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. HTL-0039732 in Malignant Mesothelioma Drug Details: HTL-0039732 is under development for the treatment of microsatellite...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Cellular Immunotherapy For Oncology 1 in Triple-Negative Breast Cancer (TNBC)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Cellular Immunotherapy For Oncology 1 in Triple-Negative Breast Cancer (TNBC) Drug Details:Cellular immunotherapy is under investigation...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Isunakinra in Pancreatic Cancer
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Isunakinra in Pancreatic Cancer Drug Details: Isunakinra (EBI-005) was under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Epcoritamab in Follicular Lymphoma
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Epcoritamab in Follicular Lymphoma Drug Details: Epcoritamab-Bysp (Epkinly) is a monoclonal antibody which acts...
-
Product Insights
Colorectal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Colorectal Cancer Pipeline Drugs Market Overview Colorectal cancer starts in the colon or the rectum. It begins as a growth called a polyp on the inner lining of the colon or rectum. Symptoms include abdominal pain and tenderness in the lower abdomen, blood in the stool, diarrhea, constipation, change in bowel habits, narrow stools, and weight loss with no known reasons. Risk factors for colorectal cancer include smoking, heavy alcohol use, inflammatory bowel disease (IBD), and family history. Treatment includes...
-
Product Insights
Huntington Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Huntington's disease (HD) is an inherited disease that causes certain nerve cells in the brain to waste away. This is a familial disease that is passed on from parent to child through a mutation in their genes. Early symptoms of HD include uncontrolled movements, clumsiness, and balance problems. Later, HD can take away the ability to walk, talk, and swallow. The Huntington Disease pipeline market research report provides comprehensive information on the therapeutics under development for Huntington Disease (Central Nervous...
-
Product Insights
Non-Small Cell Lung Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Non-Small Cell Lung Cancer Pipeline Drugs Market Report Overview Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. NSCLC is a cancer (malignancy) that originates in the tissues of the lungs or the cells lining the airways. Symptoms of lung cancer usually occur in the later stages of the disease. The signs and symptoms include a persistent cough that may get worse over time, trouble breathing or shortness of breath, constant chest pain or discomfort, bloody...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.